TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03166072

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-vision rehabilitation program
Description: Low Vision Rehabilitation Program includes functional vision assessments (low-vision refraction), prescription of a variety of visual aids including microscopes, magnifiers, telescopes, absorptive filters and electronic spectacle eyewear, large print books, and automatic self-transcending meditation plus essential skills for daily living and mobility training offered by CNIB including demonstration of visual aids as well as training on proper use of visual aids.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Intervention
Description: Participants will continue to receive treatment as usual
Study: NCT04402541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5339
Description: 25mg and 75mg capsules
Study: NCT00086645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram hydrobromide
Description: 10mg/5ml solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: up to equivalent of 20 mg of active comparator daily
Study: NCT03423524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropure 1.2.3.
Description: Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per eye will be implanted
Study: NCT04453176

Intervention type: OTHER
Intervention: Patient Satisfaction
Description: Patient satisfaction evaluated with EVAN G questionnaire

Intervention type: OTHER
Intervention: Patient Satisfaction
Description: Patient satisfaction evaluated with EVAN G questionnaire
Study: NCT01073761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir then atazanavir/ritonavir
Description: Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days~Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days
Study: NCT03600207

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex training
Description: The training program contains stretching, mobilizing, strengthening exercises on the trunk and hip muscles and a proprioceptive training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex training
Description: The training program contains stretching, mobilizing, strengthening exercises on the trunk and hip muscles and a proprioceptive training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragm training
Description: The training program contains strengthening exercises on the diaphragm muscle.
Study: NCT00884676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:~* Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)~* Schedule B: Day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:~* Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)~* Schedule B: Day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
Study: NCT04161781

Intervention type: DRUG
Intervention: 18F-BMS-986229 Injection
Description: Single injection prior to scan

Intervention type: DRUG
Intervention: IV 18F-BMS-986229
Description: 370 MBq administered intravenously prior to scan

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT Scan
Description: Whole-body PET/CT (80 mA)

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT Scan
Description: Whole-body PET/CT (80 mA)
Study: NCT05696379

Intervention type: OTHER
Intervention: Angiography derived index of micro-circulatory resistance (Angio-IMR)
Description: Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention.

Intervention type: OTHER
Intervention: Angiography derived index of micro-circulatory resistance (Angio-IMR)
Description: Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention.

Intervention type: OTHER
Intervention: Angiography derived index of micro-circulatory resistance (Angio-IMR)
Description: Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention.

Intervention type: OTHER
Intervention: Angiography derived index of micro-circulatory resistance (Angio-IMR)
Description: Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention.
Study: NCT02933437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ajmaline
Description: Ajmaline 1milligram/kilogram max dose as bolus intravenous over 10 minutes with continuous ECG monitoring
Study: NCT00884676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
Study: NCT02096744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catapres-TTS-1
Description: Catapres-TTS-1 Oppanol
Study: NCT01799291

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Decision Making Tutorial
Description: A web-based presentation focused on key cognitive de-biasing strategies, including helping clinician participants: consider alternative diagnoses (e.g., symptom checklists); decrease reliance on memory (e.g., mnemonics); and incorporate Bayesian reasoning (e.g., actuarial approaches).
Study: NCT04059328

Intervention type: PROCEDURE
Intervention: Surgical training
Description: This was a gyn laparoscopy training and simulation course
Study: NCT03719716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticipatory care planning letter
Description: Patient letter to take to GP and GP literature
Study: NCT02098889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyoscine-N-butyl bromide(HBB)
Description: A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor
Study: NCT02096744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention 1: Catapres-TTS-3
Description: Catapres-TTS-3 Oppanol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention 1: Catapres-TTS-3
Description: Catapres-TTS-3 Oppanol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention 2: Catapres-TTS-3
Description: Catapres-TTS-3 Vistanex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catapres-TTS-1
Description: Catapres-TTS-1 Vistanex
Study: NCT02098889

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
Study: NCT01268215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infasurf
Description: Endotracheal instillation of Infasurf once per week for three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infasurf
Description: Endotracheal instillation of Infasurf once per week for three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmicort
Description: Endotracheal instillation, once per week for three weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: None instilled through the endotracheal tube
Study: NCT02745535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir/Voxilaprevir
Study: NCT01107782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: 50 mg TDS orally until birth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 50mg tid
Study: NCT01237782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denture soaking solution
Description: Immersion of complete dentures in 200ml of a denture soaking solution for 20 minutes. Propolis solution: Spa Dent (Nissin Dental Products Inc., Kyoto, Japan).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Immersion of complete dentures in 200ml of a placebo denture soaking solution for 20 minutes.
Study: NCT02116998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-004 with Aluminum Hydroxide Adjuvant
Description: GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection.~GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens:~* GB104: ABC transporter, substrate-binding protein~* GB144: Maltose/maltodextrin binding protein, ABC transporter~* GB152: Hypothetical protein~GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen).~Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: normal saline, 0.5 mL per dose, IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae inoculation
Description: Intranasal inoculation of S. Pneumoniae (80,000 CFU/100μl per nostril) serotype 6B.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Streptococcus pneumoniae inoculation
Description: Intranasal inoculation of S. Pneumoniae (80,000 CFU/100μl per nostril) serotype 6B.
Study: NCT00459537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbinafine hydrogen chloride
Description: 10 % terbinafine hydrogen chloride (HCL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amorolfine nail lacquer
Description: 5 % amorolfine nail lacquer
Study: NCT00896649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: digital mammography
Description: standard screening mammogram

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission mammography
Description: one-time positron emission mammography to compare recall rates with that of standard mammogram
Study: NCT02096744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention 2: Catapres-TTS-3
Description: Catapres-TTS-3 Vistanex
Study: NCT01267487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin fixed doses
Description: Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT \> 480 sec. Supplemental doses of 50mg of heparin if ACT \<480 sec during CPB.~Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery.
Study: NCT02774304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: arterial line
Description: In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: arterial line
Description: In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cheetah®
Description: In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cheetah®
Description: In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
Study: NCT02032654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucloxacillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flucloxacillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for flucloxacillin)
Description: Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
Study: NCT03716752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified connective tissue graft wall with wing technique
Description: the usage of bone graft and collagen barrier to treat recession defects accompanied vertical bony defcets in posterior teeth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified connective tissue graft wall with wing technique
Description: the usage of bone graft and collagen barrier to treat recession defects accompanied vertical bony defcets in posterior teeth
Study: NCT01267487

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Heparin fixed doses
Description: Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT \> 480 sec. Supplemental doses of 50mg of heparin if ACT \<480 sec during CPB.~Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery.
Study: NCT02711046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single stage nasolabial flap
Description: The versatility of this flap has been attributed to the fact that there is often abundant non-hair-bearing skin in this well-vascularized region. The facial and infraorbital arteries are frequently cited in anatomic descriptions of the nasolabial flap. The venous drainage is believed to be via the angular and facial veins.
Study: NCT04517214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: PD-1 inhibitor

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT to the nasopharynx and neck
Description: IMRT to the nasopharynx and neck

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT to the nasopharynx and neck
Description: IMRT to the nasopharynx and neck
Study: NCT03239938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modern pain neuroscience approach
Description: The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care evidence-based physiotherapy
Description: The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
Study: NCT03346577

Intervention type: DEVICE
Intervention: stent or balloon
Description: Endovascular treatment with stent or balloon according to current practice
Study: NCT00094432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, Once daily, 8 weeks.
Study: NCT01274910

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)
Description: Patient will receive Fish Oil capsules (EPAX 6000 EE) .~Treatment: 5 capsules per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Capsules (Placebo)
Description: Patient will receive capsules which not contain fish oil.~Treatment: 5 capsules per day
Study: NCT03605290

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: REHAGAIT ANYLIZER
Description: Gait analysis instrumentation

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: REHAGAIT ANYLIZER
Description: Gait analysis instrumentation
Study: NCT01295970

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Prior to surgery, patients will have placement of scalp fiducials and undergo a contrast enhanced MRI scan. Once the patient is anesthetized or sedated, the head will be secured with a head frame and scalp fiducials will be registered to the stereotactic neuronavigation system. The tumor will then be resected and the patient will be taken to the recovery unit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: This will be delivered using Gamma Knife technology. Patients randomized to this arm will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
Study: NCT05781646

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Description: CSF samples was centrifuged at 3,000 - 4,000 X g for 15 minutes. Supernatant was removed to leave a 1-ml precipitate, which was then used for Ziehl-Neelsen AFB staining (100 μl), inoculation of MGIT culture (100 μl), and Xpert MTB/RIF testing (800 μl).
Study: NCT02517671

Intervention type: DEVICE
Group type: OTHER
Intervention: Enhanced External Counterpulsation (EECP)
Description: EECP is a non-invasive therapy that has been approved by the United States Food and Drug Administration (FDA) for the management of refractory angina and heart failure. This study is using the device to potentially improve 1.5 mile run times and VO2max in healthy volunteers.
Study: NCT03693911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: 6 digital and gamified session prevention program based on Acceptance and Commitment Therapy
Study: NCT01303744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 1x
Description: oral tablet, 1x, once a day in the morning for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 2x
Description: oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 3x
Description: oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks
Study: NCT03880344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Therapy
Description: Vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months + Normal Regular out-patient department physiotherapy
Study: NCT01267487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO continuous infusion of Protamine
Description: 25mg/hour in IV continuous infusion during first 6 PO hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO continuous infusion of Protamine
Description: 25mg/hour in IV continuous infusion during first 6 PO hours
Study: NCT03880344

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy as post-operative rehabilitation programme for 6 months.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy as post-operative rehabilitation programme for 6 months.
Study: NCT04517214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine and Cisplatin Chemotherapy
Description: Systemic chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin Chemotherapy
Description: Systemic chemotherapy
Study: NCT01267487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin and protamine titration
Description: Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.~Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin and protamine titration
Description: Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.~Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve.
Study: NCT01734161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8mg IV dexamethesone given

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo receive 50cc normal saline
Study: NCT03500380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: RC48-ADC 2.0 mg/kg IV every 14 days
Study: NCT02420548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Ed. and Youth Skills Coaching
Description: The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services as Usual
Description: Services as usual as provided by community service organizations from which the sample was drawn.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Services as usual as provided by community service organizations from which the sample was drawn.
Study: NCT04517214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy with Capecitabine
Description: Adjuvant chemotherapy after radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with Capecitabine
Description: Adjuvant chemotherapy after radiation